X4 Pharmaceuticals (XFOR) Expected to Announce Quarterly Earnings on Tuesday

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) is expected to announce its earnings results before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $1.07 million for the quarter. Persons interested in registering for the company's earnings conference call can do so using this link.

X4 Pharmaceuticals Stock Performance

NASDAQ:XFOR traded up $0.00 during midday trading on Friday, reaching $0.31. The stock had a trading volume of 949,303 shares, compared to its average volume of 2,943,995. The stock has a market capitalization of $52.53 million, a P/E ratio of -3.42 and a beta of 0.39. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80. X4 Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $1.60. The firm's fifty day simple moving average is $0.46 and its 200-day simple moving average is $0.54.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a "buy" rating and set a $1.50 price target on shares of X4 Pharmaceuticals in a report on Friday, February 7th.

Insider Activity at X4 Pharmaceuticals

In related news, CFO Adam S. Mostafa sold 74,773 shares of X4 Pharmaceuticals stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $33,647.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Paula Ragan sold 76,473 shares of X4 Pharmaceuticals stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $34,412.85. Following the sale, the chief executive officer now directly owns 1,087,386 shares of the company's stock, valued at $489,323.70. This represents a 6.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 202,663 shares of company stock valued at $91,198 in the last 90 days. 1.62% of the stock is owned by corporate insiders.

Remove Ads

Hedge Funds Weigh In On X4 Pharmaceuticals

An institutional investor recently raised its position in X4 Pharmaceuticals stock. Bank of America Corp DE lifted its position in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) by 20.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 133,502 shares of the company's stock after buying an additional 22,485 shares during the period. Bank of America Corp DE owned about 0.08% of X4 Pharmaceuticals worth $98,000 at the end of the most recent quarter. Institutional investors and hedge funds own 72.03% of the company's stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.